Quotient Bioresearch and KWS BioTest partner to deliver end-to-end anti-infectives screening

Cambridge, UK& Bristol, UK -Leading drug development service providers, Quotient Bioresearch Ltd. and KWSBioTest Ltd., have today announced a new strategic partnership to provide anovel co-ordinated approach to support the discovery and development of newantimicrobial agents.

The partnership - unveiled at the 21st EuropeanCongress of Clinical Microbiology and Infectious Diseases 2011 (ECCMID 2011) in Milan, Italy - will enable thetwo companies to provide high quality screening of anti-infectives all the wayfrom in vitro activity assays,efficacy and resistance profiling through validated models of human disease tosurveillance and clinical investigations, with full scientific support.

Dr.Ian Morrissey, Director ofAnti-Infectives at Quotient, explained: "With KWS we can provide a uniqueand fully-integrated ‘Plate to Patient' offering for ouranti-infective clients, by now including anti-virals and models of humandisease."

The new partnership has been created following a longstanding relationship betweenQuotient and KWS and represents significant expansion in the industry for bothcompanies. Sharing a number of joint customers, the synergy created throughthis collaboration will enable both companies to carry out larger integrated studieswith associated added value and efficiencies for their clients.

Prof.Neil Williams, Director of Science at KWS BioTest, is excited to formalise anagreement with Quotient. He commented: "Both companies have establishedthemselves on a basis of providing a high quality of service, scientificunderstanding and support to their clients."

For further information about Quotient Bioresearch Ltd., visit the website at www.quotientbioresearch.com/bioanalytical-sciences.  Further information aboutKWS BioTest Ltd. can be found at www.kwsbiotest.co.uk.

About Quotient Bioresearch Ltd.

Quotient Bioresearch is a leadingprovider of early-stage and specialist drug development services topharmaceutical, biotechnology, and medical-device clients worldwide. Thecompany offers a wide range of drug development services through its three keyfocus areas: Chemistry and Metabolism, Bioanalytical Sciences, includingMicrobiology, and Clinical. Quotient has grown rapidly in the past 3 years,through a combination of acquisition-led and organic growth.

An early acquisition for Quotientwas London-based GR Micro Ltd., bringing to the group more than 25 years'experience in antimicrobial discovery and development, and now availed of state-of-the-art, purpose-built laboratories within our Cambridgeshiresite.  Internationally recognised as leaders in providing true expertisein antimicrobial development, we are dedicated to supporting projects of allsizes, from early discovery through to late-phase clinical trials and globalresistance surveillance studies.

About KWSBioTest Ltd.

KWS BioTest Ltd was established in2004 as a CRO, bringing together internationally renowned scientificexpertise in a commercially managed environment. KWS offers a wide rangeof preclinical services from primary and secondary screens through tocomplex disease models in the areas of infection, inflammation,autoimmunity, allergy, pain and metabolic disease. In all of these areas,KWS combines analysis of traditional disease parameters with bioanalyticaland pathology services in order to work with our customers to design anddeliver bespoke programmes that meet with their expectations.

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.